The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEdinburgh Worldwide Regulatory News (EWI)

Share Price Information for Edinburgh Worldwide (EWI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 142.80
Bid: 142.80
Ask: 143.40
Change: -0.60 (-0.42%)
Spread: 0.60 (0.42%)
Open: 143.80
High: 143.80
Low: 142.20
Prev. Close: 143.40
EWI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Annual Financial Report

10 Dec 2021 07:00

RNS Number : 1982V
Edinburgh Worldwide Inv Trust PLC
10 December 2021
 

RNS Announcement: Results

 

Edinburgh Worldwide Investment Trust plc

 

Legal Entity Identifier: 213800JUA8RKIDDLH380

Regulated Information Classification: Additional regulated information required to be disclosed under the applicable laws.

The following is the results announcement for the year to 31 October 2021 which was approved by the Board on 9 December 2021.

 

Results for the year to 31 October 2021

 

¾ Over the year to 31 October 2021 the Company's net asset value per share, cum income with debt at fair value, increased by 18.3% and the share price by 11.1%. The comparative index, the S&P Global Small Cap Index* total return, increased by 35.9% in sterling terms.

¾ A number of the Company's holdings contributed to the positive performance, notably: Tesla, an electric car, autonomous driving and solar energy company, Codexis, an industrial and pharmaceutical enzyme developer, Upwork, an online freelancing and recruitment services platform and unlisted PsiQuantum, a developer of commercial quantum computing. In addition, the formerly private company QuantumScape, a developer of solid state lithium metal batteries for electric cars, and Oxford Nanopore, a DNA sequencer, both of which listed during the year.

¾ The Company's portfolio has been managed with a focus on the opportunity set lower down the market capitalisation spectrum since the end of January 2014. It is pleasing to note the 280.7% growth in the NAV since then is significantly ahead of the 149.9% achieved by the comparative index.

¾ No final dividend is being paid. Should the level of underlying income increase in future years, the Board will seek to distribute the minimum permissible to maintain investment trust status as the Company's objective remains that of generating capital growth.

¾ Over the course of the financial year, the Company issued over 50.9 million new shares at a premium to its NAV, raising net proceeds of £182.2 million.

¾ As at the financial year end, the Company held twelve unlisted investments accounting for 10.8% of total assets (2020 - 5.8% of total assets in nine holdings). As part of this year's Annual General Meeting business, shareholder authority is being sought to increase the permitted investment in unlisted investments from the current 15% to a proposed 25% of total assets, as measured at the time of initial investment.

 

* Source: Refinitiv and relevant underlying index providers. See disclaimer at the end of this announcement.

 

For a definition of terms see Glossary of Terms and Alternative Performance Measures at the end of this announcement.

 

Edinburgh Worldwide's objective is the achievement of long term capital growth by investing primarily in listed companies throughout the world. The Trust has total assets of £1,407.5 million (before deduction of loans of £66.2 million) as at 31 October 2021.

Edinburgh Worldwide is managed by Baillie Gifford & Co Limited, the Edinburgh based fund management group with over £330 billion under management and advice as at 9 December 2021.

 

Past performance is not a guide to future performance.

The value of an investment and any income from it is not guaranteed and may go down as well as up and investors may not get back the amount invested. This is because the share price is determined by the changing conditions in the relevant stock markets in which the Company invests and by the supply and demand for the Company's shares. Investment in investment trusts should be regarded as medium to long-term. You can find up to date performance information about Edinburgh Worldwide on the Edinburgh Worldwide page of the Managers' website at edinburghworldwide.co.uk

Neither the contents of the Managers' website nor the contents of any website accessible from hyperlinks on the Managers' website (or any other website) is incorporated into, or forms part of, this announcement.

 

10 December 2021

 

For further information please contact:

Anzelm Cydzik, Baillie Gifford & Co Mark Knight, Director, Four Communications

Tel: 0131 275 2000 Tel: 0203 697 4200 or 07803 75

 

Chairman's Statement

 

Performance

In the year to 31 October 2021, the Company's net asset value('NAV') per share, when calculated by deducting borrowings at fair value, increased by 18.3% and the share price by 11.1%, both in total return terms. The comparative index, the S&P Global Small Cap Index* total return, increased by 35.9% in sterling terms during this period. The Company finished the year with a market capitalisation of £1,294.6 million and total assets of £1,407.5 million. Over the course of the financial year the share price averaged a 0.7% premium to net assets, with borrowings deducted at fair value. Portfolio turnover was 9.1% compared to 8.4% for the Company's financial year to 31 October 2020 and the ongoing charge has reduced to 0.66% from 0.72%. The Company's portfolio has been managed with a focus on the opportunity set lower down the market capitalisation spectrum since the end of January 2014. It is pleasing to note the 280.7% growth in the NAV since then is significantly ahead of the 149.9% achieved by the comparative index. The chart below shows the distribution of returns for all the stocks held within the portfolio since 31 January 2014; each bar representing the return of each stock whilst held in the portfolio. This cumulative period holding analysis shows the broad distribution of returns achieved by the holdings from time of initial purchase to 31 October 2021 or the date in which the holding was fully sold from the portfolio.

 

Asymmetry of Returns

 

 

 

Whilst it is understandably disappointing to report relative underperformance for the year to 31 October 2021, this should be set in the context of positive absolute returns and this being the first financial year of relative NAV underperformance since the financial year to 31 October 2016. Over the year, the top contributors to relative and absolute performance included Tesla, an electric car, autonomous driving and solar energy company, Codexis, an industrial and pharmaceutical enzyme developer, Upwork, an online freelancing and recruitment services platform and unlisted PsiQuantum, a developer of commercial quantum computing. In addition, the formerly private company QuantumScape, a developer of solid state lithium metal batteries for electric cars, and Oxford Nanopore, a DNA sequencer, both of which listed during the year. The top detractors to relative and absolute performance over the year are names that rank amongst the top contributors to performance over five years: LendingTree, an online consumer finance marketplace, MarketAxess, an electronic bond trading platform, and Ocado, an online grocery retailer and technology provider.

 

Share Buybacks, Treasury and Issuance

The Company will once again be seeking to renew its share buyback, issuance and treasury share authorities. The buyback facility is sought to allow the Company to buy back its own shares when the discount is substantial in absolute terms and relative to its peers. Issuance, either from treasury or of new shares, will only be undertaken at a premium to the prevailing NAV, with debt calculated at par, in order to satisfy natural market demand. Issuance at a premium enhances the NAV per share for existing shareholders, dilutes ongoing costs and helps with the trading liquidity of the shares of the Company.

Over the course of the last financial year, the Company issued 50.9 million new shares at a premium to its NAV, raising net proceeds of £182.2 million and increasing the NAV per share by 0.32%. This equates to 14.4% of the issued share capital at the start of the year. Growth in assets along with the Company's tiered management fee has contributed to the reduction in the Company's ongoing charges for the year.

 

Unlisted Investments

The Managers have shareholder authority to invest up to 15% of the Company's total assets, at the time of initial investment, in unlisted investments. As at the Company's year end, the portfolio weighting in private companies stood at 10.8% of total assets, invested in twelve companies (2020 - 5.8% of total assets in nine companies). Six new private company investments were made during the year: Relativity Space, a 3D printing and aerospace launch company, QuantumScape which has now listed, Astranis Space Technologies, a geostationary communications satellite operator and manufacturer, Shine Technologies (Illuminated Holdings), producer of medical radioscopes, Snyk, a software security developer, and Lightning Labs, a money transfer software developer.

At the Company's Annual General meeting ('AGM') held on 23 January 2019, shareholders approved an increase in the permissible limit of investment in unlisted investments from 5% to 15% of total assets at the time of initial investment. As part of the 2 February 2022 AGM business, the Board is seeking shareholder approval to increase this authority to 25% as the Board and Managers are of the view that private companies are becoming an increasingly relevant part of the Company's objective; to invest in a global portfolio of initially immature entrepreneurial companies, typically with a market capitalisation of less than US$5 billion at the time of initial investment, which are believed to offer long-term growth potential.

Accelerating improvements in technology are reducing the capital and time needed for young businesses to both experiment with and scale their product offerings. For many new entrepreneurs this is delaying the need for a public fundraising or resulting in some really exceptional companies entering the stock market when they are larger and more mature, and the rising availability of private capital is serving to compound this shift. In 2006, 18 private companies globally had valuations of over US$500 million with an aggregate value of US$18 billion. As of the end of 2020 there were 923 companies with valuations of over US$500 million, and an aggregate value of US$2.2 trillion. This makes this market approximately the same size as the S&P MidCap 400 index. As at 31 October 2021, Baillie Gifford had £4 billion invested in 73 private companies across 14 countries.

Given the potential for this to be an increasingly valuable source of investment ideas for Edinburgh Worldwide and Baillie Gifford's growing capability to deploy capital here, the Board would like the Managers to have flexibility to invest a greater portion of the Company's assets in private companies as suitable opportunities arise. This would allow better scope for long term asymmetry to play out within existing private holdings without limiting the Managers' ability to invest opportunistically in new ideas in the future. The number of private holdings is expected to continue increasing gradually whilst several more businesses will also undertake public listings in the fullness of time, as has been the case to date with, for example, Oxford Nanopore, QuantumScape and Spire Global this year.

Over the last seven years, Edinburgh Worldwide has invested in eighteen private companies and the weighting has risen from 0% to a little under 11% of the Company's assets as at 31 October 2021. Depending on the outcome of the shareholder vote, and in due course reflecting on future investor sentiment at the time towards private companies and the investable opportunity set, and the performance being generated from such holdings, the Board will keep the matter of the weighting to unlisted investments under review.

 

 

Borrowings

The extent and range of equity gearing is discussed by the Board and Managers at each Board meeting. Both parties agree that the Company should typically be geared to equities to maximise potential returns, with the current aspirational parameters set at +5% to +15% of shareholders' funds. Over the year, the invested equity gearing ranged between -2.7% and +2.6%, and stood at +2.5% of shareholders' funds at the financial year end (2020 - +0.9%).

During the period, the Company entered into a new five year £100 million multi-currency revolving credit facility, with The Royal Bank of Scotland International Limited, with an expiry date of 9 June 2026. This facility is in addition to the existing five year £25 million multi-currency revolving credit facility, with National Australia Bank Limited, with an expiry date of 29 June 2023 and the five year £36 million multi-currency revolving credit facility, with National Australia Bank Limited, with an expiry date of 30 September 2024. As at 31 October 2021, the Company had drawings of €7,200,000, US$53,150,000 and £21,300,000.

 

Earnings and Dividend

The Company's objective is that of generating capital growth and investors should not expect any income from this investment. This year the net revenue return per share was a negative 0.62p (2020 - negative 0.46p per share). As the revenue account is running at a deficit, no final dividend is being recommended by the Board. Should the level of underlying income increase in future years, the Board will seek to distribute to shareholders the minimum permissible to maintain investment trust status by way of a final dividend.

 

Board Composition and Ceiling on Aggregate Remuneration

During the course of the year, Mr William Ducas retired from the Board. I would like to place on record my and the Board's thanks for his contribution to Company discussions and his pragmatic advice and guidance. There are no changes expected in Board composition over the coming year although Mr Donald Cameron has highlighted to colleagues that he is unlikely to stand for re-election at the Company's 2023 AGM.

 

The current aggregate remuneration ceiling for Directors' fees is set at £200,000 per annum. Based on the level of aggregate remuneration expected to be paid for the financial year ending 31 October 2022 (£182,500 - being £40,500 for the Chairman, £27,000 for each Director, an additional £6,000 for the Chairman of the Audit and Management Engagement Committee and an additional £1,000 for the Senior Independent Director), should the Board wish to appoint a new Director the aggregate fees would likely exceed the current authorised limit. Accordingly, it is proposed that, pursuant to Resolution 14, as set out in the Notice of Annual General Meeting, the maximum permissible aggregate amount of fees payable to the Directors be increased to £250,000 per annum in aggregate.

 

Investment Outlook

Markets continued to rise notably until the tail end of the first quarter of 2021 and subsequently declined due in part to concerns regarding future inflation and dislocated supply, largely as a result of Covid-19 and the measures put in place to curb its impact on businesses. More recently, market sentiment has been pushed and pulled by attempts at 'normality' against a backdrop of new virus variants and a Chinese regulatory clampdown. However, there are now signs that markets are becoming more fundamentals-led rather than momentum driven.

As mentioned in the past, your portfolio managers continue to direct their efforts to picking the best entrepreneurial, immature growth companies that create and exploit investment opportunities, and which exhibit excellent long-term growth prospects and the potential for positive long term returns wherever they are listed and whatever the macro backdrop. Whilst markets exhibit volatility, the investment trust structure permits the portfolio managers and discerning long-term investors to take positions in exciting, dynamic and innovative companies for the long term.

An overview of the portfolio is provided on pages 13 and 15 of the Annual Report and .Financial Statements.

 

 

 

Annual General Meeting

As part of the Company's AGM business, the Company is seeking to update its Articles of Association, details of which can be found on page 71 of the Annual Report and Financial Statements. The principal proposed change regards the ability to hold hybrid AGMs, permitting, in extremis circumstances such as those resulting from Covid-19, shareholders to attend by electronic means as well as in person. It is however intended that future meetings be physical unless restrictions prohibiting this are in force at the time.

It is anticipated that the Company's next AGM will be held in person and be held at Baillie Gifford's offices in Edinburgh at 12 noon on Wednesday 2 February 2022. The Managers will be presenting and I and the Board look to see as many of you there as possible.

Should the situation change, further information will be made available through the Company's website at edinburghworldwide.co.uk and the London Stock Exchange regulatory news service. Further information, including the proposed resolutions and information on the deadlines for submitting votes by proxy should you not be able to attend, can be found on pages 68 to 70 of the Annual Report and Financial Statements. Shareholders who hold shares

in their own name on the main register will be provided with a Form of Proxy and there are also special arrangements for holders of shares through the abrdn Investment Trusts Share Plan, Individual Savings Account and Investment Plan for Children who are provided with a Form of Direction. If you hold shares through a share platform or other nominee, the Board would encourage you to contact these organisations directly as soon as possible to arrange for you to submit votes in advance of the AGM.

 

 

Henry CT Strutt

Chairman

9 December 2021

 

 

 

* Source: Refinitiv and relevant underlying index providers. See disclaimer at the end of this announcement.

calculated by dividing the value of sales by the average of the opening and closing value of the investment portfolio.

For a definition of terms see Glossary of Terms and Alternative Performance Measures at the end of this announcement.

Past performance is not a guide to future performance. 

Managers' Review

 

What We Seek to Offer

Edinburgh Worldwide Investment Trust's philosophy is one where we seek ambitious, problem-solving companies with what we believe to be excellent long-term growth potential. By identifying attractive growth companies earlier, we seek to benefit during the most dynamic phase of a company's lifecycle and retain ownership of successful companies as they grow and thrive. It's an approach that requires patience, a long-term mindset and recognition that progress in young companies rarely happens in a straight line. The solutions that our holdings are working towards are not designed to be transient or modestly incremental. Should they succeed the likelihood is that they will embed themselves as key drivers of their respective industries in the years that follow.

Our style of investing is one in which many of our ideas will ultimately fail to live up to our lofty aspirations for them. Rather than fret about this we view it as an inevitable outcome of our bias towards immature companies with long-term potential. Occasionally, that failure can be abrupt, with clear implications for the viability of the business and the capital invested. For others, it will be much less spectacular: a solid business emerges with acceptable returns for investors but with nagging frustration that the outcomes could have been much better. But some companies (and it's the minority) will both surprise and delight: their initial traction in opening new avenues for growth will likely make our original hypothesis look rather feeble. This wide range of outcomes is evident in the asymmetry of returns chart shown in the Chairman's statement.

It's from this extreme dispersion of outcomes that we actively desire long-term returns to be moulded. Sorting the deep winners from the losers and the also-rans takes both time and patience. The differentiating factors that drive that outcome will most likely be formed within the individual companies themselves, refined further by their operating environment and lastly polished through the actions of their shareholders. Attempting to take the readout on that experiment at anything less than five years will probably not tell you very much. It's for this reason that we view the NAV performance in the year ended 31 October 2021 as more an observation. It's effectively a snapshot that probably conveys more about the prevailing narrative within stock markets than a useful barometer on how our approach is faring. With Edinburgh Worldwide's NAV having risen by 203% over the five years to the end of October 2021 (versus the 69% rise in the comparative index*) we think the evidence leans towards our philosophy having long-term merit.

Implicit in the dispersion of winners versus losers discussed above is the direct link between a company's progress and the magnitude of the investment returns that it can generate. A company's operational success will translate ultimately into cashflow, the present value of which investors can use to judge a company's intrinsic value. But the notion of a company's cashflow (or its more relatable cousin, profits) is not an abstract one that resides in a CFO's or investment analyst's spreadsheet. It's the output of a myriad of interactions and decisions involving the company and its surroundings. How those cashflows are produced and how they impact a wider group of stakeholders, society and the environment, will also be crucial determinants of not only their size, but their long-term durability and permissibility. Consequently, the notion of sustainability, in all its guises, is something we believe to be deeply ingrained in bona fide long-term growth investing.

In Edinburgh Worldwide, we think our remit and philosophy enable us to go a step further. We have long found that the most interesting companies are invariably those that position themselves on the frontiers of socio-economic change, rather than shy away from it. They are the ones that address the most pressing questions, seek to tackle the largest problems and build solutions that seek to drive the world forward. For such companies, sustainability is not just the how they go about operating, it's also the why: why they exist, why society should care and why, ultimately, they might be an outstanding investment opportunity.

We think our focus on companies pursuing durable long-term progress, improving outcomes and reducing both costs and frictions across a range of diverse areas, means that the portfolio is well-positioned to participate in the change that will follow. Moreover, through provision of primary capital to private companies we think that role can become more active.

 

Observations and Portfolio Update

The past year has seen stock markets wrestle with a world trying to get back to normal and the oscillations from optimism to fear seem even more pronounced than usual. Second and third order effects related to the pandemic will likely persist but predicting these with conviction is difficult and can arguably be a distraction from our core task (although we are mindful of the opportunities they may create in markets prone to overreaction). In the near-term, we expect that supply-demand imbalances will persist, behaviours of consumers and businesses will be hard to predict and the overall level of uncertainty will remain elevated. Against such a backdrop we expect the narrative and typical time horizon in equity markets to remain skewed to a 'here and now' mindset.

The second and third quarter reporting periods have been atypical in that companies were annualising the immediate impact of the pandemic. For some companies this presents as a recovery-type boost but for several of our companies, especially those that were natural beneficiaries of the pandemic (e.g. Telemedicine providers or ecommerce businesses) this period has been one where the comparator has been tough. As previously discussed, we are more intrigued by how the fortunes of such businesses have been transformed on a multi-year, perhaps even a multi-decade basis. Annualising an extreme base effect often excites stock markets but it tends to tell you very little of relevance to the real long-term progress of a business.

For companies such as Teladoc, the stock market's questioning relates to a modest near-term membership growth opportunity. Yet we think the evidence of the company going much deeper with existing members is much more reflective of the value being built. Likewise, with Ocado the shrinking basket size and limited near-term growth could be expected from a business that was running at well above optimal capacity a year ago. Much more relevant in our minds is the increasingly delighted noises emerging from its grocery partners as they go live with their Ocado-enabled facilities.

A notable area of weakness in the portfolio has been our Chinese stocks. Referring to our holdings by geographic location always feels rather odd to us but is probably justified in this context, given the challenges that have emerged. We prefer to simplify the debate on China investing to two key axes. The first axis is a geopolitical one. The roots here extend well beyond the recent months but the 'who lists where and why' and 'where do companies keep sensitive customer data' arguments don't feel like they will be resolved imminently. The second axis is arguably a bit easier for investors to have a considered view on, namely domestic Chinese companies where the accrued power and influence have begun to sit at odds with the more holistic, openly socialist approach of the governing party. Certain sectors have been singled out for intervention, most obviously those involved in aspects of lending, education and gaming. For some of our holdings such as Huya and Agora this has created headwinds, even if the impact on these businesses is much more indirect than direct.

In actively looking for companies that are innovating and trying to move the world forward we believe we are concentrating on an opportunity set whose own actions will be the greatest determinant of their own success or failure. As observers along frontiers of innovation in a wide range of industries and applications, we continue to be excited by the opportunities that abound. Consequently, we feel that the current portfolio and investment approach is as relevant as it's ever been. We think this is well illustrated by the eleven new purchases we reported on in the Interim Report to the end of April 2021 and is reinforced by the further five names (two listed businesses and three private) we purchased over the subsequent six months. We introduce these below:

- ITM Power is a UK company which designs and manufactures PEM electrolysers (proton exchange membrane). Electrolysers are devices that produce hydrogen gas using electricity and water as inputs (with oxygen gas as a side-product). The hydrogen gas can then be used as chemical feedstock or it can be consumed in a fuel cell to yield back energy and water. With the declining cost of renewable energy and mounting imperative across society and industry of net zero targets, we see the prospect of the much-heralded hydrogen economy being transformed over the coming decades. Green electrolyser-derived hydrogen is likely to be the most viable route for many heavy emitting industries to decarbonise. While batteries are a practical energy store in many applications, when the energy storage requirement is long term and the utilisation conditions are more demanding, the benefits of hydrogen come to the fore. ITM is among the major electrolyser producers that cater to this opportunity. It focuses uniquely on the more differentiated PEM type electrolysers and has the largest PEM manufacturing capacity.

¾ Shine Technologies (Illuminated Holdings) is a private nuclear technology company, with an initial focus on the production of medical radioisotopes for diagnostic and therapeutic procedures. The company's approach offers

several advantages here, being cleaner, safer and more affordable to operate than legacy infrastructure. It also addresses a growing gap between the supply and demand for these important products within healthcare systems around the world. Longer term, Shine has a path to leverage this technology and operating experience into larger and more transformational opportunities around nuclear waste recycling and the production of clean fusion energy.

- Snyk is a private IT security company focused on the growing opportunity in application development. It offers a toolkit for software developers that allows them to detect vulnerabilities and fix bugs themselves, embedding security functions at an early stage and significantly improving the pace at which the software can be signed off and released for use. We think such tools will become increasingly standard in the software application development cycle as Snyk has the synergistic advantage of appealing to both the developer community and those tasked to maintain the robustness of a company's overall IT operations. As more code is tested against, and modified by, Snyk's toolkit we think the company will be well positioned to create a valuable data advantage that will become increasingly hard for others to replicate.

- Angelalign is China's leading domestic provider of invisible orthodontic products. The clear aligners market in China is relatively small but growing rapidly, underpinned by secular drivers like greater awareness of dental care and aesthetics associated with increasing disposable incomes. Angelalign effectively democratises access to such orthodontic treatments by empowering all dental professionals, not just the limited number of orthodontic specialists. We are encouraged by its success so far and with the founding management team still in place, we believe it can become the dominant player in this rapidly expanding market.

- Lightning Labs is a private San Francisco-based company which was founded to drive the adoption of, and to commercialise, the Bitcoin Lightning Network, an open source project which operates as a second layer built on top of Bitcoin. The Lightning Network substantially improves Bitcoin's utility by enabling scalable, instantaneous and nearly free payments. The software designed and maintained by Lightning Labs is quickly gaining traction among developers seeking to build Lightning applications. It has the potential to establish itself as the go-to codebase not only for payment applications but for incipient higher-level protocols for programmatically routing any data/value over the Lightning Network. It does this instantly, privately and at exceptionally low cost. While early, we are intrigued by the potential for Lightning Labs to become a key infrastructure provider in the emerging Bitcoin ecosystem.

We sold the position in Cloudera following a takeover offer from private equity. We also exited the holding in Yext. Our original investment hypothesis was that Yext was well-placed to carve out a highly differentiated position in the increasingly important area of corporate knowledge management. The product roadmap since has diverged from what we perceive to be Yext's core skillset and competitive strength.

 

 

 

 

 

* S&P Global Small Cap Index total return (in sterling terms). Source: Refinitiv and relevant underlying index providers. See disclaimer at the end of this announcement.

Investment Philosophy

 

Most small businesses are destined to stay small given their limited scope for both structural growth and meaningful differentiation. Such businesses constitute the bulk of the smaller companies' universe yet are of no appeal to us. However, what is intriguing about the smaller companies' universe is that it contains a subset of immature but potentially high growth companies. By identifying attractive growth companies earlier we seek to benefit from growth at an earlier stage in a company's lifecycle and retain ownership of successful companies as they grow and thrive; we see our role as investing in what are potentially the larger companies of the future as opposed to the smaller companies of today.

We are looking to concentrate on the part of the market where we believe our analytical effort and the pursuit of genuinely transformational growth can be better exploited. The focus at time of initial investment is on younger, more immature companies that are global and exhibiting strong growth.

It is important to remember that big successful ideas typically start out as small, tentative and unproven. Early iterations are easy to dismiss as unworkable but experimentation with, and evolution of, an initially raw concept can, over time, yield huge commercial relevance. Our philosophy involves weighing up what is proven and tangible alongside what has promise and long term potential. Integral to this approach is recognising the role of innovation in business development; it provides the fuel for business creation, growth and long term competitive differentiation. Consequently, identifying companies that value innovation, having both a cultural acceptance of it and a means to develop commercial opportunities around it, is fundamental to our investment approach.

Growth companies, especially those which are young and hard to model, are difficult businesses to value. The wide range of potential outcomes and profitability that is heavily skewed to future years is a combination of uncertainties that many investors struggle with. We do not have all the answers but by approaching the challenge with a genuine long term perspective, accepting a degree of uncertainty, backing robust innovation and entrepreneurial management, we believe we are well positioned to identify the smaller businesses most likely to shape the world in which we live. As technological advancements encroach into an increasing pool of opportunity, the rate and extent of growth that a small business can achieve, in a relatively short period of time, is almost unrecognisable to that of a few years ago. Innovative smaller businesses that are unburdened by the legacy of historic business practices, or those willing to adapt to change, are best positioned to harness this opportunity.

 

Baillie Gifford Statement on Stewardship

Reclaiming Activism for Long-Term Investors

 

Reclaiming Activism for Long-Term Investors

Baillie Gifford's over-arching ethos is that we are 'actual' investors. We have a responsibility to behave as supportive and constructively engaged long-term investors. We invest in companies at different stages in their evolution, across vastly different industries and geographies and we celebrate their uniqueness. Consequently, we are wary of prescriptive policies and rules, believing that these often run counter to thoughtful and beneficial corporate stewardship. Our approach favours a small number of simple principles which help shape our interactions with companies.

 

Our Stewardship Principles

 

Prioritisation of long-term value creation

We encourage company management and their boards to be ambitious and focus their investments on long-term value creation. We understand that it is easy for businesses to be influenced by short-sighted demands for profit maximisation but believe these often lead to sub-optimal long-term outcomes. We regard it as our responsibility to steer businesses away from destructive financial engineering towards activities that create genuine economic value

over the long run. We are happy that our value will often be in supporting management when others do not.

 

A constructive and purposeful board

We believe that boards play a key role in supporting corporate success and representing the interests of minority shareholders. There is no fixed formula, but it is our expectation that boards have the resources, cognitive diversity and information they need to fulfil these responsibilities. We believe that a board works best when there is strong independent representation able to assist, advise and constructively test the thinking of management.

 

Long-term focused remuneration with stretching targets

We look for remuneration policies that are simple, transparent and reward superior strategic and operational endeavour. We believe incentive schemes can be important in driving behaviour, and we encourage policies which create alignment with genuine long-term shareholders. We are accepting of significant pay-outs to executives if these are commensurate with outstanding long-run value creation, but plans should not reward mediocre outcomes. We think that performance hurdles should be skewed towards long-term results and that remuneration plans should be subject to shareholder approval.

 

Fair treatment of stakeholders

We believe it is in the long-term interests of companies to maintain strong relationships with all stakeholders, treating employees, customers, suppliers, governments and regulators in a fair and transparent manner. We do not believe in one-size-fits-all governance and we recognise that different shareholder structures are appropriate for different businesses. However, regardless of structure, companies must always respect the rights of all equity owners.

 

Sustainable business practices

We look for companies to act as responsible corporate citizens, working within the spirit and not just the letter of the laws and regulations that govern them. We believe that corporate success will only be sustained if a business's long-run impact on society and the environment is taken into account. Management and boards should therefore understand and regularly review this aspect of their activities, disclosing such information publicly alongside plans for ongoing improvement.

 

 

 

Income statement

 

 

For the year ended

31 October 2021

For the year ended

31 October 2020

 

Revenue

£'000

Capital

£'000

Total

£'000

 

Revenue

£'000

Capital

£'000

Total

£'000

 

Gains on investments

178,323 

178,323 

 

329,236 

329,236 

 

Currency losses

(1,631)

(1,631)

 

(1,360)

(1,360)

 

Income (note 2)

827 

827 

 

773 

773 

 

Investment management fee

(1,952)

(5,857)

(7,809)

 

(1,145)

(3,434)

(4,579)

 

Other administrative expenses

(907)

(907)

 

(715)

(715)

 

Net return before finance costs and taxation

(2,032)

170,835 

168,803 

 

(1,087)

324,442 

323,355

 

Finance costs of borrowings

(340)

(1,019)

(1,359)

 

(331)

(991)

(1,322)

 

Net return before taxation

(2,372)

169,816 

167,444 

 

(1,418)

323,451 

322,033 

 

Tax

(50)

(50)

 

(61)

(61)

 

Net return after taxation

(2,422)

169,816 

167,394 

 

(1,479)

323,451 

321,972 

 

Net return per ordinary share (note 4)

(0.62p)

43.37p

42.75p

 

(0.46p)

100.89p

100.43p

 

          

 

The total column of this Statement represents the profit and loss account of the Company. The supplementary revenue and capital columns are prepared under guidance published by the Association of Investment Companies.

All revenue and capital items in this statement derive from continuing operations.

A Statement of Comprehensive Income is not required as the Company does not have any other comprehensive income and the net return after taxation is both the profit and comprehensive income for the year.

 

 

Balance sheet

 

 

 

At 31 October 2021

£'000

At 31 October 2020

£'000

Fixed assets

 

 

Investments held at fair value through profit or loss (note 6)

1,376,365 

1,002,194 

Current assets

 

 

Debtors

322 

160 

Cash and cash equivalents

33,127 

40,894 

 

33,449 

41,054 

Creditors

 

 

Amounts falling due within one year (note 8)

(68,459)

(51,514)

Net current liabilities

(35,010)

(10,460)

Net assets

1,341,355 

991,734 

 

 

 

Capital and reserves

 

 

Share capital

4,052 

3,543 

Share premium account

497,999 

316,281 

Special reserve

35,220 

35,220 

Capital reserve

808,197 

638,381 

Revenue reserve

(4,113)

(1,691)

Shareholders' funds

1,341,355 

991,734 

Net asset value per ordinary share

331.03p

279.90p

Ordinary shares in issue (note 9)

405,203,695 

354,318,695 

 

 

 

 

Statement of changes in equity

 

For the year ended 31 October 2021

 

 

Share

 capital

£'000

Share premium account

£'000

 

Special reserve

£'000

 

Capital reserve*

£'000

 

Revenue

 reserve

£'000

 

Shareholders'

funds

£'000

Shareholders' funds at 1 November 2020

3,543

316,281

35,220

638,381

(1,691)

991,734

Ordinary shares issued (note 9)

509

181,718

-

-

182,227

Net return after taxation

-

-

-

169,816

(2,422)

167,394

Shareholders' funds at 31 October 2021

4,052

497,999

35,220

808,197

(4,113)

1,341,355

 

 

For the year ended 31 October 2020

 

 

Share

 capital

£'000

Share premium account

£'000

 

Special reserve

£'000

 

Capital reserve*

£'000

 

Revenue

 reserve

£'000

 

Shareholders'

funds

£'000

Shareholders' funds at 1 November 2019

3,026

183,754

35,220

314,930

(212)

536,718

Ordinary shares issued (note 9)

517

132,527

-

-

133,044

Net return after taxation

-

-

-

323,451

(1,479)

321,972

Shareholders' funds at 31 October 2020

3,543

316,281

35,220

638,381

(1,691)

991,734

 

* The capital reserve balance as at 31 October 2021 includes investment holdings gains on fixed asset investments of £591,196,000 (2020 - gains of £476,217,000).

 

 

 

Cash flow statement

 

 

For the year ended

 31 October 2021

For the year ended

 31 October 2020

 

£'000

£'000

£'000

£'000

Cash flows from operating activities

 

 

 

 

Net return before taxation

 

167,444 

 

322,033 

Net gains on investments

 

(178,323)

 

(329,236)

Currency losses

 

1,631 

 

1,360 

Finance costs of borrowings

 

1,359 

 

1,322 

Overseas withholding tax incurred

 

(50)

 

(62)

Changes in debtors and creditors

 

416 

 

623 

Cash from operations*

 

(7,523)

 

(3,960)

Interest paid

 

(1,244)

 

(1,378)

Net cash outflow from operating activities

 

(8,767)

 

(5,338)

Cash flows from investing activities

 

 

 

 

Acquisitions of investments

(305,256)

 

(164,843)

 

Disposals of investments

108,235 

 

65,917 

 

Net cash outflow from investing activities

 

(197,021)

 

(98,926)

Cash flows from financing activities

 

 

 

 

Ordinary shares issued (note 9)

182,227 

 

133,044 

 

Bank loans drawn down

318,406 

 

198,933 

 

Bank loans repaid

(299,373)

 

(198,933)

 

Net cash inflow from financing activities

 

201,260 

 

133,044 

(Decrease)/increase in cash and cash equivalents

 

(4,528)

 

28,780 

Exchange movements

 

(3,239)

 

(1,228)

Cash and cash equivalents at 1 November

 

40,894 

 

13,342 

Cash and cash equivalents at 31 October

 

33,127 

 

40,894 

 

 

 

 

 

* Cash from operations includes dividends received of £781,000 (2020 - £727,000) and no deposit interest received

 (2020 - £60,000)

 

 

Twenty largest holdings and Twelve Month Performance at

31 October 2021

 

 

 

 

 

Name

 

 

Business

 

 

Country

Fair Value

2021

£'000

% of

total

assets*

Absolute† performance

%

Relative† performance

%

Tesla

Electric vehicles, autonomous driving

and solar energy

USA

85,450

6.1

171.4

99.6

Zillow#

US online real estate portal

USA

51,095

3.6

10.5

(18.7)

Alnylam

Pharmaceuticals

Drug developer focussed on

harnessing gene silencing technology

USA

46,706

3.3

22.6

(9.8)

Ocado

Online grocery retailer and technology

provider

UK

45,747

3.3

(20.8)

(41.7)

Upwork

Online freelancing and recruitment

services platform

USA

41,225

2.9

141.3

77.5

STAAR Surgical

Ophthalmic implants for vision

correction

USA

39,236

2.8

54.0

13.3

Space Exploration

Technologies#U

Designs, manufactures and launches

advanced rockets and spacecraft

USA

38,016

2.6

73.4

27.6

Codexis

Industrial and pharmaceutical enzyme

developer

USA

33,953

2.4

145.7

80.8

PsiQuantum#U

Developer of commercial quantum

computing

USA

33,757

2.4

266.1

169.3

MarketAxess

Electronic bond trading platform

USA

33,339

2.4

(28.1)

(47.1)

Teladoc

Telemedicine services provider

USA

32,447

2.3

(28.2)

(47.2)

Novocure

Manufacturer of medical devices for

cancer treatment

USA

27,476

2.0

(20.8)

(41.7)

Chegg

Online educational company

USA

26,259

1.9

(23.7)

(43.8)

BlackLine

Enterprise financial software provider

USA

25,922

1.8

22.6

(9.8)

Oxford Nanopore

Technologies#P

Novel DNA sequencing technology

UK

25,910

1.8

113.5

57.1

Kingdee International

Software

Enterprise management software

provider

China

24,591

1.7

19.0

(12.4)

Zai Lab ADR

Chinese bio-pharmaceutical

development and distribution company

China

23,525

1.7

19.8

(11.9)

Ceres Power

Holding

Developer of fuel cells

UK

23,497

1.7

79.5

32.0

Xero

Cloud based accounting software for

small and medium-sized enterprises

New

Zealand

21,537

1.5

36.9

0.7

Appian

Enterprise software developer

USA

20,944

1.5

48.1

9.0

 

 

 

700,632

49.7

 

 

        

* Total assets comprises all assets held less all liabilities other than liabilities in the form of borrowings.

Absolute and relative performance has been calculated on a total return basis over the period 1 November 2020 to 31 October 2021. Absolute performance is in sterling terms; relative performance is against S&P Global Small Cap Index (in sterling terms).

# More than one line of stock held. Holding information represents the aggregates of both lines of stock.

Figures relate to part-period returns where security has been purchased or added to during the period.

U Denotes unlisted security.

P Denotes listed security previously held in the portfolio as an unlisted security.

 

Source: Baillie Gifford/StatPro and relevant underlying index providers. See disclaimer at the end of this announcement.

Past performance is not a guide to future performance.

 

List of investments as at 31 October 2021

 

 

 

 

 

Name

 

 

 

Business

 

 

 

Country

Fair

Value

2021

£'000

 

% of

total

assets

Fair

Value

2020

£'000

Tesla

Electric vehicles, autonomous driving and solar

energy

USA

 

85,450

 

6.1

 

51,332

Zillow Class C

US online real estate portal

USA

44,097

3.1

33,235

Zillow Class A

US online real estate portal

USA

6,998

0.5

6,272

 

 

 

51,095

3.6

39,507

Alnylam

Pharmaceuticals

Drug developer focussed on harnessing gene

silencing technology

USA

 

46,706

 

3.3

 

32,238

Ocado

Online grocery retailer and technology provider

UK

45,747

3.3

49,460

Upwork

Online freelancing and recruitment services

platform

USA

 

41,225

 

2.9

 

12,250

STAAR Surgical

Ophthalmic implants for vision correction

USA

39,236

2.8

21,787

Space Exploration

Technologies Series N

Preferred U

Designs, manufactures and launches advanced

rockets and spacecraft

USA

 

 

21,788

 

 

1.5

 

 

12,374

Space Exploration

Technologies Series J

Preferred U

Designs, manufactures and launches advanced

rockets and spacecraft

USA

 

 

9,884

 

 

0.7

 

 

5,613

Space Exploration

Technologies Series K

Preferred U

Designs, manufactures and launches advanced

rockets and spacecraft

USA

 

 

4,506

 

 

0.3

 

 

2,559

Space Exploration

Technologies Class A

Common U

Designs, manufactures and launches advanced

rockets and spacecraft

USA

 

 

1,405

 

 

0.1

 

 

-

Space Exploration

Technologies Class C

Common U

Designs, manufactures and launches advanced

rockets and spacecraft

USA

 

 

433

 

 

0.0

 

 

-

 

 

 

38,016

2.6

20,546

Codexis

Industrial and pharmaceutical enzyme

developer

USA

 

33,953

 

2.4

 

11,961

PsiQuantum Series C

Preferred U

Developer of commercial quantum computing

USA

 

20,626

 

1.5

 

3,867

PsiQuantum Series D

Preferred U

Developer of commercial quantum computing

USA

 

13,131

 

0.9

 

-

 

 

 

33,757

2.4

3,867

MarketAxess

Electronic bond trading platform

USA

33,339

2.4

46,703

Teladoc

Telemedicine services provider

USA

32,447

2.3

26,308

Novocure

Manufacturer of medical devices for cancer

treatment

USA

 

27,476

 

2.0

 

28,789

Chegg

Online educational company

USA

26,259

1.9

32,964

BlackLine

Enterprise financial software provider

USA

25,922

1.8

19,058

Oxford Nanopore

Technologies

Novel DNA sequencing technology

UK

 

1,132

 

0.1

 

11,276

Oxford Nanopore

Technologies P

Novel DNA sequencing technology

UK

 

24,778

 

1.7

 

-

 

 

 

25,910

1.8

11,276

Kingdee International

Software

Enterprise management software provider

China

 

24,591

 

1.7

 

17,622

Zai Lab ADR

Chinese bio-pharmaceutical development and

distribution company

China

 

23,525

 

1.7

 

16,207

Ceres Power Holding

Developer of fuel cells

UK

23,497

1.7

11,924

Xero

Cloud based accounting software for small and

medium-sized enterprises

New

Zealand

 

21,537

 

1.5

 

15,729

Appian

Enterprise software developer

USA

20,944

1.5

14,160

       

 

List of investments as at 31 October 2021 (ctd)

 

 

 

 

Name

 

 

 

Business

 

 

 

Country

Fair

Value

2021

£'000

 

% of

total

assets

Fair

Value

2020

£'000

QuantumScape P

Solid-state batteries for electric vehicles

USA

19,255

1.4

-

Sprout Social

Cloud based software for social media

management

USA

 

18,599

 

1.3

 

-

Genmab

Antibody based drug development

Denmark

18,001

1.3

12,691

Exact Sciences

Non-invasive molecular tests for early cancer

detection

USA

 

17,900

 

1.3

 

14,746

PureTech Health

IP commercialisation focused on healthcare

UK

17,701

1.2

12,951

Axon Enterprise

Law enforcement equipment and software

provider

USA

 

17,351

 

1.2

 

7,810

Everbridge

Critical event management software provider

USA

17,253

1.2

12,019

Wayfair

Online furniture and homeware retailer

USA

15,783

1.1

16,691

CyberArk Software

Cyber security solutions provider

Israel

15,115

1.1

8,827

Tandem Diabetes Care

Manufacturer of insulin pumps for diabetic

patients

USA

 

14,746

 

1.0

 

12,508

AeroVironment

Small unmanned aircraft and tactical missile

systems

USA

 

14,318

 

1.0

 

13,022

ITM Power

Hydrogen energy solutions manufacturer

UK

13,811

1.0

-

Trupanion

Pet health insurance provider

USA

13,790

1.0

10,236

LendingTree

Online consumer finance marketplace

USA

13,786

1.0

25,321

ShockWave Medical

Medical devices manufacturer

USA

13,366

1.0

4,538

Ambarella

Video compression and image processing

semiconductors

USA

 

13,232

 

0.9

 

4,129

Genus

Livestock breeding and technology services

UK

12,842

0.9

9,517

Zuora

Enterprise sales management software

USA

12,451

0.9

1,823

Akili Interactive Labs

Series C Preferred U

 

Digital medicine company

USA

 

3,614

 

0.3

 

4,600

Akili Interactive Labs

Series D Preferred U

 

Digital medicine company

USA

 

8,754

 

0.6

 

-

 

 

 

12,368

0.9

4,600

Pacira BioSciences

Opioid free analgesics developer

USA

12,235

0.9

10,510

Adaptimmune

Therapeutics ADR

 

Cell therapies for cancer treatment

UK

 

12,135

 

0.9

 

8,494

M3

Online medical database

Japan

12,017

0.9

14,556

Cardlytics

Digital advertising platform

USA

11,770

0.8

-

LiveRamp

Marketing technology company

USA

11,523

0.8

13,392

MonotaRO

Online business supplies

Japan

11,489

0.8

14,932

Relativity Space Series D

Preferred U

 

3D printing and aerospace launch company

USA

 

7,812

 

0.5

 

-

Relativity Space Series E

Preferred U

 

3D printing and aerospace launch company

USA

 

3,648

 

0.3

 

-

 

 

 

11,460

0.8

-

Sutro Biopharma

Biotechnology company focused on next

generation protein therapeutics

USA

 

11,041

 

0.8

 

6,462

InfoMart

Online platform for restaurant supplies

Japan

11,039

0.8

9,936

IPG Photonics

High-power fibre lasers

USA

10,473

0.8

10,613

American Superconductor

Designs and manufactures power systems and

superconducting wire

USA

 

10,292

 

0.7

 

6,071

Temenos Group

Banking software provider

Switzerland

10,210

0.7

7,594

JFrog

Software development tools and management

Israel

9,860

0.7

-

Astranis Space

Technologies Series C

Preferred U

Communication satellite manufacturing and

operation

 

 

USA

 

 

9,329

 

 

0.7

 

 

-

LivePerson

Messaging tools for business and customer

interactions

 

USA

 

9,315

 

0.7

 

10,247

Splunk

Data diagnostics

USA

8,884

0.6

11,316

 

List of investments as at 31 October 2021 (ctd)

 

 

 

 

Name

 

 

 

Business

 

 

 

Country

Fair

Value

2020

£'000

 

% of

total

assets

Fair

Value

2019

£'000

Shine Technologies

(Illuminated Holdings)

Serices C-5 Preferred U

 

 

Medical radioisotope production

 

 

USA

 

 

8,754

 

 

0.6

 

 

-

iRobot

Consumer robotics and connected devices

USA

7,809

0.6

7,896

Quanterix

Ultra-sensitive protein analysers

USA

7,742

0.6

-

Snyk Ordinary Shares U

Security software

UK

2,736

0.2

-

Snyk Series F Preferred U

Security software

UK

4,560

0.4

-

 

 

 

7,296

0.6

-

Lightning Labs Series B

Preferred U

Lightning software that enables users to send

and receive money

 

USA

 

7,295

 

0.5

 

-

Renishaw

Measurement and calibration equipment

UK

7,055

0.5

7,863

Q2 Holdings

Cloud based virtual banking solutions provider

USA

6,997

0.5

8,625

Graphcore Series D2 Preferred U

Specialised processor chips for machine

learning applications

 

UK

 

5,244

 

0.4

 

4,247

Graphcore Series E Preferred U

Specialised processor chips for machine

learning applications

 

UK

 

1,672

 

0.1

 

-

 

 

 

6,916

0.5

4,247

freee K.K.

Cloud based accounting software for small and

medium-sized enterprises

 

Japan

 

6,833

 

0.5

 

-

Avacta Group

Affinity based diagnostic reagents and

therapeutics

 

UK

 

6,642

 

0.5

 

9,218

IP Group

Intellectual property commercialisation

UK

6,601

0.4

4,324

Sensirion Holding

Manufacturer of gas and flow sensors

Switzerland

5,939

0.4

2,400

SEEK

Online recruitment portal

Australia

5,846

0.4

3,812

Reaction Engines U

Advanced heat exchange company

UK

5,750

0.4

5,750

Digimarc

Digital watermarking technology provider

USA

5,693

0.4

3,791

Ilika

Discovery and development of novel materials

for mass market applications

 

UK

 

5,379

 

0.4

 

3,348

Galapagos

Clinical stage biotechnology company focussing

on autoimmune and fibrosis diseases

 

Belgium

 

5,187

 

0.4

 

8,806

Oxford Instruments

Advanced instrumentation and equipment

provider

 

UK

 

5,144

 

0.4

 

3,526

Rightmove

UK online property portal

UK

4,771

0.3

4,263

Tabula Rasa HealthCare

Cloud-based healthcare software developer

USA

4,711

0.3

3,686

Berkeley Lights

Biotechnology tools focused on cell

characterisation

 

USA

 

4,186

 

0.3

 

7,274

Nanobiotix ADR

Nanomedicine company focused on cancer

radiotherapy

 

France

 

4,066

 

0.3

 

-

Agora ADR

Voice and video platform technology provider

China

4,056

0.3

4,987

BASE

Commerce platform for small and medium-sized

enterprises

 

Japan

 

3,951

 

0.3

 

-

Huya ADR

A live game streaming platform

China

3,725

0.3

5,036

Baozun SPN ADR

Chinese e-commerce solution provider

China

3,712

0.3

8,314

Spire Global P

Satellite powered data collection and analysis

company

 

USA

 

3,570

 

0.3

 

-

Morphosys

Antibody based drug discovery platform

Germany

3,451

0.2

5,866

PeptiDream

Peptide based drug discovery platform

Japan

3,377

0.2

6,843

Stratasys

3D printer manufacturer

USA

3,327

0.2

1,429

Victrex

High-performance thermo-plastics

UK

2,909

0.2

2,345

KSQ Therapeutics Series

C Preferred U

Biotechnology target identification company

 

USA

 

2,744

 

0.2

 

1,925

CEVA

Licenses IP to the semiconductor industry

USA

2,743

0.2

2,573

ASOS

Online fashion retailer

UK

2,532

0.2

4,494

EverQuote

Online marketplace for buying insurance

USA

2,329

0.2

4,853

 

 

 

 

 

 

 

 

 

 

 

 

 

List of investments as at 31 October 2021 (ctd)

 

 

 

 

Name

 

 

 

Business

 

 

 

Country

Fair

Value

2021

£'000

 

% of

total

assets

Fair

Value

2020

£'000

C4X Discovery Holdings

Rational drug design and optimisation

UK

2,178

0.2

510

C4X Discovery Warrants

Software to aid drug design

UK

37

0.0

-

 

 

 

2,215

0.2

510

NuCana SPN ADR

Next generation chemotherapy developer

UK

2,178

0.1

4,523

Cellectis

Genetic engineering for cell based therapies

France

 

1,915

 

0.1

 

2,966

AxoGen

Regenerative medicine and nerve repair

company

 

USA

 

1,880

 

0.1

 

1,645

New Horizon Health

Cancer screening company

China

1,870

0.1

-

Cosmo Pharmaceuticals

Therapies for gastrointestinal diseases

 

Italy

 

1,846

 

0.1

 

2,084

Benefitfocus

Employee benefits software provider

USA

1,810

0.1

1,807

Catapult Group

International

Analytics and data collection technology for

sports teams and athletes

 

Australia

 

1,752

 

0.1

 

1,638

Rubius Therapeutics

Developer of novel therapies using engineered

red blood cells

 

USA

 

1,596

 

0.1

 

505

4D Pharma

Microbiome biology therapeutics

UK

1,105

0.1

1,971

4D Pharma Warrants

Microbiome biology therapeutics

UK

0

0.0

35

 

 

 

1,105

0.1

2,006

Uxin ADR

Online Chinese used car marketplace

China

984

0.1

420

Chinook Therapeutics

(formerly Aduro

Biotechnology)

Immunotherapy drug development

 

 

USA

 

 

917

 

 

0.1

 

 

1,117

Chinook Therapeutics

(formerly Aduro

Biotechnology) CVR Line

Immunotherapy drug development

 

 

USA

 

 

0

 

 

0.0

 

 

-

 

 

 

917

0.1

1,117

Kaleido Biosciences

Microbiome chemistry therapeutics

USA

898

0.1

913

Summit Therapeutics

Developer of novel antibiotics

USA

835

0.1

479

Unity Biotechnology P

Biotechnology company seeking to develop

anti-ageing therapies

 

USA

 

595

 

0.0

 

1,018

Ricardo

Engineering services provider

UK

577

0.0

483

Adicet Bio (formerly

resTORbio)

Biotechnology company focussed on age

related disorders

 

USA

 

553

 

0.0

 

728

Adicet Bio (formerly res

TORbio) CVR Line

Biotechnology company focussed on age

related disorders

USA

 

0

 

0.0

 

-

 

 

 

553

0.0

728

Angelalign Technology

Medical devices manufacturer

China

261

0.0

-

Tissue Regenix

Regenerative medicine technology provider

UK

104

0.0

66

Xeros Technology Group

Polymer technology company with laundry and

textile applications

 

UK

 

76

 

0.0

 

93

VYNE Therapeutics

(formerly Menlo

Therapeutics)

Biopharmaceutical company focused in the

dermatology space

 

USA

 

49

 

0.0

 

248

Velocys

Gas to liquid technology

UK

27

0.0

19

Ensogo D

South East Asian e-commerce

Australia

0

0.0

0

China Lumena New

Materials S

Mines, processes and manufactures natural

thenardite products

 

China

 

0

 

0.0

 

0

Total equities

 

 

1,376,365

97.8

 

Net liquid assets

 

 

31,143

2.2

 

Total assets at fair value*

 

 

1,407,508

100.0

 

 

* Total assets comprises all assets held less all liabilities other than liabilities in the form of borrowings.

U Denotes unlisted security.

P Denotes listed security previously held in the portfolio and an unlisted security.

D Denotes delisting security.

S Denotes suspended unlisted security.

 

 

 

 

Listed

equities

%

Unlisted securities†

%

Net liquid assets

%

Total

assets

%

31 October 2021

87.0

10.8

2.2

100.0

31 October 2020

90.5

5.8

3.7

100.0

Figures represent percentage of total assets.

 Includes holdings in preference shares, ordinary shares and convertible promissory notes.

 

 

 

Distribution of total assets* by industry

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Industry Analysis

31 October 2021

% of total assets*

 

Portfolio Weightings

(relative to comparative index†)

at 31 October 2021

 

Software

17.5

 

12.1 

 

Biotechnology

15.2

 

10.8 

 

Healthcare Equipment and Supplies

7.3

 

5.3 

 

Automobiles

6.1

 

5.8 

 

Aerospace and Defence

6.0

 

5.1 

 

Healthcare Technology

4.6

 

4.0 

 

Electrical Equipment

4.1

 

2.3 

 

Real Estate Management and Development

3.6

 

1.5 

 

Professional Services

3.3

 

1.7 

 

Life Sciences Tools and Services

3.3

 

2.0 

 

Food and Staples Retailing

3.3

 

2.4 

 

Technology Hardware, Storage and Peripherals

3.1

 

2.5 

 

Capital Markets

2.8

 

(0.1)

 

Electronic Equipment, Instruments and Components

2.1

 

(0.3)

 

IT Services

1.9

 

(0.4)

 

Diversified Consumer Services

1.9

 

1.1 

 

Pharmaceuticals

1.8

 

0.1 

 

Internet and Direct Marketing Retail

1.5

 

1.0 

 

Auto Components

1.4

 

(0.2)

 

Semiconductors and Semiconductor Equipment

1.1

 

(1.9)

 

Insurance

1.0

 

(1.6)

 

Consumer Finance

1.0

 

0.2 

 

Interactive Media and Services

0.9

 

0.2 

 

Media

0.8

 

(0.7)

 

Trading Companies and Distributors

0.8

 

(0.6)

 

Household Durables

0.6

 

(1.1)

 

Entertainment

0.3

 

(0.8)

 

Chemicals

0.2

 

(2.9)

 

Internet and Catalogue Retail

0.2

 

0.2 

 

Healthcare Providers and Services

0.1

 

(1.9)

 

Machinery

 

(4.2)

 

Energy Equipment and Services

 

(0.6)

Net Liquid Assets

2.2

 

 

Total assets*

100.0

 

 

* Total assets comprises all assets held less all liabilities other than liabilities in the form of borrowings.

S&P Global Small Cap Index (in sterling terms). Weightings exclude industries where the Company has no exposure.

 

See disclaimer at the end of this announcement.

 

 

 

 

Distribution of total assets

 

Geographical Analysis

 

 

31 October 2021

%

31 October 2020

%

North America

 

66.9

63.5

 

 

USA

66.9

63.5

 

Europe

 

20.9

20.7

 

 

United Kingdom

15.6

15.5

 

 

Eurozone

1.1

2.2

 

 

Developed Europe (non euro)

4.2

3.0

 

Asia

 

8.0

10.1

 

 

Japan

3.5

5.0

 

 

China

4.5

5.1

 

Australasia

 

2.0

2.0

 

 

Australia

0.5

0.5

 

 

New Zealand

1.5

1.5

 

Total equities

97.8

96.3

 

Net liquid assets

2.2

3.7

 

Total assets*

100.0

100.0

 

 

Sectoral Analysis

 

 

31 October 2021

%

 

31 October 2020

%

 

Communication Services

 

5.6

 

5.6

 

Consumer Discretionary

 

15.0

 

16.5

 

Financials

 

 4.9

 

8.3

 

Healthcare

 

32.3

 

32.5

 

Industrials

 

14.2

 

9.2

 

Information Technology

 

25.6

 

24.0

 

Materials

 

0.2

 

0.2

 

Net Liquid Assets

 

2.2

 

3.7

 

Total assets*

 

100.0

 

100.0

 

 * Total assets comprises all assets held less all liabilities other than liabilities in the form of borrowings.

 

 

 

 

 

Notes to the condensed financial statements (unaudited)

 

1.

Basis of Accounting

The Financial Statements for the year to 31 October 2021 have been prepared in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and on the basis of the accounting policies which are unchanged from the prior year and have been applied consistently.

2.

Income

2021

£'000

2020

£'000

Income from investments

 

 

UK dividends

411

154

Overseas dividends

402

538

Overseas interest

14

21

 

827

713

Other income

 

 

 

Deposit interest

-

60

 

Total income

827

773

 

Total income comprises:

 

 

 

Dividends from financial assets designated at fair value through profit or loss

813

692

 

Interest from financial assets designated at fair value through profit or loss

14

21

 

Interest from financial assets not at fair value through profit or loss

-

60

 

 

827

773

3.

Investment Manager

The Company has appointed Baillie Gifford & Co Limited, a wholly owned subsidiary of Baillie Gifford & Co, as its Alternative Investment Fund Manager and Company Secretaries. Baillie Gifford & Co Limited has delegated portfolio management services to Baillie Gifford & Co. Dealing activity and transaction reporting have been further sub-delegated to Baillie Gifford Overseas Limited and Baillie Gifford Asia (Hong Kong) Limited. The Management Agreement can be terminated on three months' notice.

The annual management fee is 0.75% on the first £50m of net assets, 0.65% on the next £200m of net assets and 0.55% on the remaining net assets. Management fees are calculated and payable quarterly.

 

 

 

4.

 

Net return per ordinary share

 

Revenue

2021

 Capital

 

Total

 

Revenue

2020

Capital

 

Total

Net return after taxation

(0.62p)

 

43.37p

42.75p

 

(0.46p)

100.89p

100.43p

 

 

 

 

 

 

 

 

 

Revenue return per ordinary share is based on the net revenue loss after taxation of £2,422,000 (2020 - net revenue loss of £1,479,000) and on 391,579,802 (2020 - 320,606,304) ordinary shares, being the weighted average number of ordinary shares during the year.

 

Capital return per ordinary share is based on the net capital gain for the financial year of £169,816,000 (2020 - net capital gain of £323,451,000) and on 391,579,802 (2020 - 320,606,304) ordinary shares, being the weighted average number of ordinary shares in issue during the year.

 

There are no dilutive or potentially dilutive shares in issue.

5.

Dividends

There are no dividends paid and proposed in respect of the financial year. There is no revenue available for distribution by way of dividend for the year to 31 October 2021. Revenue loss of £2,442,000 (2020 - revenue loss of £1,479,000) which is the basis on which the requirements of section 1158 of the Corporation Tax Act are considered.

 

6.

Fair Value Hierarchy

 

 

 

 

 

As at 31 October 2021

Level 1

£'000

Level 2

£'000

Level 3

£'000

Total

£'000

Listed equities

1,224,768

-

-

1,224,768

 

Unlisted ordinary shares

-

-

18,235

18,235

 

Unlisted preference shares*

-

-

133,362

133,362

 

Unlisted convertible promissory note

-

-

-

-

 

Total financial asset investments

1,224,768

-

151,597

1,376,365

 

 

 

 

 

 

 

As at 31 October 2020

Level 1

£'000

Level 2

£'000

Level 3

£'000

Total

£'000

Listed equities

941,393

-

-

941,393

 

Unlisted ordinary shares

-

-

23,213

23,213

 

unlisted preference shares*

-

-

37,319

37,319

 

Unlisted convertible promissory note

-

-

269

269

 

Total financial asset investments

941,393

-

60,801

1,002,194

 

* The investments in preference shares are not classified as equity holdings as they include liquidation preference rights that determine the repayment (or multiple thereof) of the original investment in the event of a liquidation event such as a take-over.

 

Investments in securities are financial assets designated at fair value through profit or loss. In accordance with Financial Reporting Standard 102, the tables above provide an analysis of these investments based on the fair value hierarchy described below, which reflects the reliability and significance of the information used to measure their fair value.

 

Fair Value Hierarchy

The fair value hierarchy used to analyse the fair values of financial assets is described below. The levels are determined by the lowest (that is the least reliable or least independently observable) level of input that is significant to the fair value measurement for the individual investment in its entirety as follows:

Level 1 - using unadjusted quoted prices for identical instruments in an active market;

Level 2 - using inputs, other than quoted prices included within Level 1, that are directly or indirectly observable (based on market data); and

Level 3 - using inputs that are unobservable (for which market data is unavailable).

 

7.

Transaction Costs

The Company incurred transaction costs on purchases of £129,000 (2020 - £49,000) and on sales of £32,000 (2020 - £21,000).

8.

Bank Loans

During the period, the Company entered into a new five year £100 million multi-currency revolving credit facility, with The Royal Bank of Scotland International Limited, with an expiry date of 9 June 2026. This facility is in addition to the existing five year £25 million multi-currency revolving credit facility, with National Australia Bank Limited, with an expiry date of 29 June 2023 and the five year £36 million multi-currency revolving credit facility, with National Australia Bank Limited, with an expiry date of 30 September 2024. As at 31 October 2021, the Company had drawings of €7,200,000, US$53,150,000 and £21,300,000 under the £100 million revolving rate facility. There were no drawings under the £25 million or £36 million facility. At 31 October 2020 the drawings were €1,410,900, US$18,545,250 and £9,185,037 under the £25 million revolving credit facility and €1,410,900, US$18,545,250 and £8,314,963 under the £36 million revolving credit facility.

 

The sterling value of the bank loans at 31 October 2021 was £66,153,000 (31 October 2020 - £48,728,000).

9.

Share Capital

The Company has authority to allot shares under section 551 of the Companies Act 2006. The Board has authorised use of this authority to issue new shares at a premium to net asset value in order to enhance the net asset value per share for existing shareholders and improve the liquidity of the Company's shares. In the year to 31 October 2021 the Company issued a total of 50,885,000 shares on a non pre-emptive basis (nominal value of £509,000, representing 14.4% of the issued share capital at 31 October 2020) at a premium to net asset value (on the basis of debt valued at book value) raising net proceeds of £182,227,000 (In the year to 31 October 2020 - 51,720,000 shares with a nominal value of £517,000, representing 17.1% of the issued share capital at 31 October 2019 raising net proceeds of £133,044,000).

 

The Company also has authority to buy back shares. In the year to 31 October 2021 no ordinary shares were bought back therefore the Company's authority remains unchanged at 54,588,887 ordinary shares.

10.

Analysis of Change in Debt

 

 

 

 

 

 

 

 

 

At 31 October

2020

£'000

 

Cash

flows

£'000

 

Exchange movement

£'000

At 31 October

2021

£'000

 

 

Cash and cash equivalents

40,894

(4,528)

(3,239)

33,127

 

 

Loans due within one year

(48,728)

(19,033)

1,608

(66,153)

 

 

 

(7,834)

(23,561)

(1,631)

(33,026)

 

 

 

 

 

 

 

 

11.

Financial Information

The financial information set out above does not constitute the Company's statutory accounts for the year ended 31 October 2021 or the year ended 31 October 2020 but is derived from those accounts. Statutory accounts for the period to 31 October 2020 have been delivered to the Registrar of Companies, and those for the year to 31 October 2021 will be delivered in due course. The auditor has reported on those accounts; the reports were (i) unqualified, (ii) did not include a reference to any matters to which the auditor drew attention by way of emphasis without qualifying their report and (iii) did not contain a statement under section 498 (2) or (3) of the Companies Act 2006.

 

 

 

 

 

 

          

Glossary of Terms and Alternative Performance Measures ('APM')

An alternative performance measure is a financial measure of historical or future financial performance, financial position, or cash flows, other than a financial measure defined or specified in the applicable financial reporting framework.

 

Total Assets

The total value of all assets held less all liabilities other than liabilities in the form of borrowings.

 

Net Asset Value ('NAV')

Also described as shareholders' funds, net asset value is the value of total assets less liabilities (including borrowings). Net asset value can be calculated on the basis of borrowings stated at book value and fair value. An explanation of each basis is provided below. The net asset value per share is calculated by dividing this amount by the number of ordinary shares in issue excluding any shares held in treasury.

 

Net Asset Value (Borrowings at Book Value)

Borrowings are valued at their nominal book value. The value of the borrowings at book and fair value are set out on page 67 of the Annual Report and Financial Statements.

 

Net Asset Value (Borrowings at Fair Value) (APM)

Borrowings are valued at an estimate of their market value. The value of the borrowings at book and fair value are set out on page 67 of the Annual Report and Financial Statements.

 

Net Asset Value (Reconciliation of NAV at Book Value to NAV at Fair Value)

 

 

31 October

2021

31 October

2020

Net Asset Value per ordinary share (borrowings at book value)

331.03p

279.90p

Shareholders' funds (borrowings at book value)

£1,341,355,000

£991,734,000

Add: book value of borrowings

£66,153,000

£48,728,000

Less: fair value of borrowings

(£66,153,000)

(£48,728,000)

Shareholders' funds (borrowings at fair value)

£1,341,355,000

£991,734,000

Number of shares in issue

405,203,695

354,318,695

Net Asset Value per ordinary share (borrowings at fair value)

331.03p

279.90p

 

At 31 October 2021 and 31 October 2020 all borrowings are in the form of short term floating rate borrowings and their fair value is considered equal to their book value, hence there is no difference in the net asset value at book value and fair value.

Net Liquid Assets

Net liquid assets comprise current assets less current liabilities, excluding borrowings.

Discount/Premium (APM)

As stock markets and share prices vary, an investment trust's share price is rarely the same as its net asset value. When the share price is lower than the net asset value per share it is said to be trading at a discount. The size of the discount is calculated by subtracting the share price from the net asset value per share and is usually expressed as a percentage of the net asset value per share. If the share price is higher than the net asset value per share, this situation is called a premium.

 

 

 

31 October

2021

31 October

2020

Net asset value per share

(a)

331.03p

279.90p

Share price

(b)

319.50p

287.50p

(Discount)/premium

((b)-(a)) ÷(a)

(3.5%)

2.7%

 

Total Return (APM)

The total return is the return to shareholders after reinvesting the net dividend on the date that the share price goes ex-dividend.

 

Compound Annual Return (APM)

The compound annual return converts the return over a period of longer than one year to a constant annual rate of return applied to the compound value at the start of each year.

 

 

Glossary of Terms and Alternative Performance Measures ('APM') (Ctd)

 

Ongoing Charges (APM)

The total recurring expenses (excluding the Company's cost of dealing in investments and borrowing costs) incurred by the Company as a percentage of the average net asset value (with debt at fair value). The ongoing charges have been calculated on the basis prescribed by the Association of Investment Companies.

 

Ongoing Charges Calculation

 

 

31 October

2021

31 October

2020

Investment management fee

£7,809,000

£4,579,000

Other administrative expenses

£907,000

£715,000

Total Expenses (a)

£8,716,000

£5,294,000

Average daily cum-income net asset value (with debt at fair value) (b)

£1,324,089,000

£736,409,000

Ongoing charges (a) as a percentage of (b)

0.66%

0.72%

 

Gearing (APM)

At its simplest, gearing is borrowing. Just like any other public company, an investment trust can borrow money to invest in additional investments for its portfolio. The effect of the borrowing on the shareholders' assets is called 'gearing'. If the Company's assets grow, the shareholders' assets grow proportionately more because the debt remains the same. But if the value of the Company's assets falls, the situation is reversed. Gearing can therefore enhance performance in rising markets but can adversely impact performance in falling markets.

Gearing is the Company's borrowings at book value less cash and cash equivalents (including any outstanding trade settlements) expressed as a percentage of shareholders' funds.

 

 

31 October

2021

31 October

2020

Borrowings (at book value)

£66,153,000

£48,728,000

Less: cash and cash equivalents

(£33,127,000)

(£40,894,000)

Less: sales for subsequent settlement

-

Add: purchases for subsequent settlement

£1,173,000

Adjusted borrowings (a)

£33,026,000

£9,007,000

Shareholders' funds (b)

£1,341,355,000

£991,734,000

Gearing: (a) as a percentage of (b)

2%

1%

 

Potential gearing is the Company's borrowings expressed as a percentage of shareholders' funds.

 

 

31 October

2021

31 October

2020

Borrowings (at book value) (a)

£66,153,000

£48,728,000

Shareholders' funds (b)

£1,341,355,000

£991,734,000

Potential gearing (a) as a percentage of (b)

5%

5%

 

Leverage (APM)

For the purposes of the Alternative Investment Fund Managers Regulations, leverage is any method which increases the Company's exposure, including the borrowing of cash and the use of derivatives. It is expressed as a ratio between the Company's exposure and its net asset value and can be calculated on a gross and a commitment method. Under the gross method, exposure represents the sum of the Company's positions after the deduction of sterling cash balances, without taking into account any hedging and netting arrangements. Under the commitment method, exposure is calculated without the deduction of sterling cash balances and after certain hedging and netting positions are offset against each other.

 

 

Glossary of Terms and Alternative Performance Measures ('APM') (Ctd)

 

Active Share (APM)

Active share, a measure of how actively a portfolio is managed, is the percentage of the portfolio that differs from its comparative index. It is calculated by deducting from 100 the percentage of the portfolio that overlaps with the comparative index. An active share of 100 indicates no overlap with the index and an active share of zero indicates a portfolio that tracks the index.

 

Share Split

A share split (or stock split) is the process by which a company divides its existing shares into multiple shares. Although the number of shares outstanding increases, the total value of the shares remains the same with respect to the pre-split value.

 

Unlisted Company

An unlisted company means a company whose shares are not available to the general public for trading and not listed on a stock exchange.

 

The Annual Report and Financial Statements will be available on the Edinburgh Worldwide page of the Managers' website edinburghworldwide.co.uk† on or around 22 December 2021.

 

 

Neither the contents of the Company's website nor the contents of any website accessible from hyperlinks on

the Company's website (or any other website) is incorporated into, or forms part of, this announcement.

 

 

Third Party Data Provider Disclaimer

No third party data provider ('Provider') makes any warranty, express or implied, as to the accuracy, completeness or timeliness of the data contained herewith nor as to the results to be obtained by recipients of the data. No Provider shall in any way be liable to any recipient of the data for any inaccuracies, errors or omissions in the index data included in this document, regardless of cause, or for any damages (whether direct or indirect) resulting therefrom.

 

No Provider has any obligation to update, modify or amend the data or to otherwise notify a recipient thereof in the event that any matter stated herein changes or subsequently becomes inaccurate.

 

Without limiting the foregoing, no Provider shall have any liability whatsoever to you, whether in contract (including under an indemnity), in tort (including negligence), under a warranty, under statute or otherwise, in respect of any loss or damage suffered by you as a result of or in connection with any opinions, recommendations, forecasts, judgements, or any other conclusions, or any course of action determined, by you or any third party, whether or not based on the content, information or materials contained herein.

 

S&P Index Data

The S&P Global Small Cap Index ('Index') is a product of S&P Dow Jones Indices LLC, a division of S&P Global, or its affiliates ('SPDJI'). Standard & Poor's® and S&P® are registered trademarks of Standard & Poor's Financial Services LLC, a division of S&P Global ('S&P'); Dow Jones® is a registered trademark of Dow Jones Trademark Holdings LLC ('Dow Jones'). Neither S&P Dow Jones Indices LLC, Dow Jones Trademark Holdings LLC, their affiliates nor their third party licensors make any representation or warranty, express or implied, as to the ability of any index to accurately represent the asset class or market sector that it purports to represent and neither S&P Dow Jones Indices LLC, Dow Jones Trademark Holdings LLC, their affiliates nor their third party licensors shall have any liability for any errors, omissions, or interruptions of any index or the data included therein.

 

- Ends -

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FR FSLFAUEFSESE
Date   Source Headline
28th May 20244:53 pmRNSTransaction in Own Shares
28th May 20242:50 pmRNSNet Asset Value(s)
28th May 202411:53 amRNSNet Asset Value(s)
24th May 20244:50 pmRNSTransaction in Own Shares
24th May 202412:22 pmRNSNet Asset Value(s)
23rd May 20244:56 pmRNSTransaction in Own Shares
23rd May 202411:29 amRNSNet Asset Value(s)
22nd May 20244:54 pmRNSTransaction in Own Shares
22nd May 202411:20 amRNSNet Asset Value(s)
21st May 20244:58 pmRNSTransaction in Own Shares
21st May 202411:32 amRNSNet Asset Value(s)
20th May 20244:47 pmRNSTransaction in Own Shares
20th May 202411:27 amRNSNet Asset Value(s)
17th May 20245:01 pmRNSTransaction in Own Shares
17th May 202411:51 amRNSNet Asset Value(s)
17th May 202410:06 amRNSHolding(s) in Company
16th May 20245:11 pmRNSTransaction in Own Shares
16th May 20241:45 pmRNSNet Asset Value(s)
15th May 20244:48 pmRNSTransaction in Own Shares
15th May 202412:32 pmRNSNet Asset Value(s)
15th May 20249:18 amRNSHolding(s) in Company
14th May 20244:50 pmRNSTransaction in Own Shares
14th May 202411:57 amRNSNet Asset Value(s)
13th May 20244:51 pmRNSTransaction in Own Shares
13th May 202411:59 amRNSNet Asset Value(s)
10th May 20244:44 pmRNSTransaction in Own Shares
10th May 202412:42 pmRNSNet Asset Value(s)
9th May 20244:51 pmRNSTransaction in Own Shares
9th May 202412:03 pmRNSNet Asset Value(s)
9th May 20249:44 amRNSHolding(s) in Company
8th May 20244:48 pmRNSTransaction in Own Shares
8th May 202411:48 amRNSNet Asset Value(s)
7th May 202412:37 pmRNSNet Asset Value(s)
7th May 202411:29 amRNSNet Asset Value(s)
7th May 20249:40 amRNSHolding(s) in Company
3rd May 20245:13 pmRNSTransaction in Own Shares
3rd May 202412:43 pmRNSNet Asset Value(s)
3rd May 202411:13 amRNSHolding(s) in Company
2nd May 20245:32 pmRNSTransaction in Own Shares
2nd May 202411:04 amRNSNet Asset Value(s)
1st May 20244:03 pmRNSClosed Period Confirmation
1st May 20243:36 pmRNSNet Asset Value(s)
1st May 202410:34 amRNSHolding(s) in Company
1st May 202410:13 amRNSTotal Voting Rights
30th Apr 20245:07 pmRNSTransaction in Own Shares
30th Apr 202412:00 pmRNSNet Asset Value(s)
29th Apr 20244:53 pmRNSTransaction in Own Shares
29th Apr 202412:34 pmRNSNet Asset Value(s)
29th Apr 20249:46 amRNSHolding(s) in Company
26th Apr 202411:47 amRNSNet Asset Value(s)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.